Regarding the investment in JOINN Bio, Zeng Zhiqiang, a managing partner at HG Capital Medical Fund, said, “HG Medical has always adhered to the investment strategy of working with the industry leader in a specific segment, and is definitely optimistic about opportunities in the CRO and CDMO field driven by the global, especially China or other emerging-market countries, upsurge of innovative medicine. JOINN Labs is an industry leader in the field of biomedical CRO through years of hard work. In addition to strong technology platform and high-quality service system, more than 60% of Chinese biopharmaceutical companies are JOINN Labs’ customer. The excellent track record and brand recognition form the foundation to extend to those customers in the area of CDMO services.
We look forward to the joint effort of HG Medical Fund and JOINN to leverage HG Medical’s resources in the field of biomedicine and clinical services to assist JOINN Bio quickly becoming a world-class biopharmaceutical CDMO. “
Ziqiang Zeng, Managing partner at Huagai
Capital Medical Fund